Fewer participants reported one or more confirmed ( @ mmol/L ) or severe nocturnal hypoglycemic events between week @ and month @ with Gla-@ ( @ vs. @ % with Gla-@ ; relative risk @ -LSB- @ % CI @-@ @ -RSB- ; P < @ ) ; nocturnal hypoglycemia incidence and event rates were also lower with Gla-@ in the first @ weeks of treatment .